Mark Van Scyoc / Shutterstock.com
24 January 2017Americas
Endo resolves FTC allegations over Lidoderm and Opana ER
Endo Pharmaceuticals yesterday settled charges brought by the Federal Trade Commission (FTC) by abandoning anti-competitive pay-for-delay agreements.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Americas
22 July 2019 Ireland-headquartered Endo Pharmaceuticals agreed to pay $2.3 million to 18 states late last week, settling allegations that the drugmaker paid a competitor to keep a generic version of pain relief drug Lidoderm off the market.
Big Pharma
7 June 2021 Endo International and Amneal Pharmaceuticals’ subsidiary, Impax Laboratories, have failed to prevent antitrust claims over a patent settlement from going to trial.
Generics
2 September 2021 The US District Court for the District of Delaware has ruled that one of Endo International’s pharma units cannot stop a generic of its blood pressure drug Vasostrict from being made.
Editor's picks
Editor's picks
Americas
22 July 2019 Ireland-headquartered Endo Pharmaceuticals agreed to pay $2.3 million to 18 states late last week, settling allegations that the drugmaker paid a competitor to keep a generic version of pain relief drug Lidoderm off the market.
Big Pharma
7 June 2021 Endo International and Amneal Pharmaceuticals’ subsidiary, Impax Laboratories, have failed to prevent antitrust claims over a patent settlement from going to trial.
Generics
2 September 2021 The US District Court for the District of Delaware has ruled that one of Endo International’s pharma units cannot stop a generic of its blood pressure drug Vasostrict from being made.
Americas
22 July 2019 Ireland-headquartered Endo Pharmaceuticals agreed to pay $2.3 million to 18 states late last week, settling allegations that the drugmaker paid a competitor to keep a generic version of pain relief drug Lidoderm off the market.
Big Pharma
7 June 2021 Endo International and Amneal Pharmaceuticals’ subsidiary, Impax Laboratories, have failed to prevent antitrust claims over a patent settlement from going to trial.
Generics
2 September 2021 The US District Court for the District of Delaware has ruled that one of Endo International’s pharma units cannot stop a generic of its blood pressure drug Vasostrict from being made.